RU2007141625A - Вариантные формы уратоксидазы и их применение - Google Patents
Вариантные формы уратоксидазы и их применение Download PDFInfo
- Publication number
- RU2007141625A RU2007141625A RU2007141625/13A RU2007141625A RU2007141625A RU 2007141625 A RU2007141625 A RU 2007141625A RU 2007141625/13 A RU2007141625/13 A RU 2007141625/13A RU 2007141625 A RU2007141625 A RU 2007141625A RU 2007141625 A RU2007141625 A RU 2007141625A
- Authority
- RU
- Russia
- Prior art keywords
- uricase
- nucleic acid
- conjugate
- polyethylene glycol
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Abstract
1. Изолированная укороченная уриказа млекопитающего, содержащая аминокислотную последовательность уриказы млекопитающего, укороченную с аминоконца или карбоксиконца или и с амино- и с карбоксиконца приблизительно на 1-13 аминокислот и дополнительно содержащая аминокислотную замену приблизительно в положении 46. ! 2. Уриказа по п.1, дополнительно содержащая аминоконцевую аминокислоту, где данной аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин. ! 3. Уриказа по п.2, где аминоконцевой аминокислотой является треонин. ! 4. Уриказа по п.1, где заменой является замена на треонин или аланин. ! 5. Уриказа по п.3, где заменой является замена на треонин. ! 6. Уриказа по п.5, содержащая аминокислотную последовательность SEQ ID № 8. ! 7. Уриказа по любому из пп.1-6, где уриказа конъюгирована с полимером. ! 8. Конъюгат полиэтиленгликоль-уриказа, содержащий уриказу по любому из пп.1-6. ! 9. Конъюгат по п.8, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы. ! 10. Конъюгат по п.9, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы. ! 11. Конъюгат по п.8, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 100 кД. ! 12. Конъюгат по п.11, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 50 кД. ! 13. Конъюгат по п.12, где каждая молекула полиэтиленгликоля имела молекулярную массу от 5 кД до 20 кД. ! 14. Конъюгат по п.13, где каждая молекула полиэтиленгликоля имела молекулярную массу приблизительно 10 кД. ! 15. Фармацевтическая композиция, содержащая уриказу по любому из пп.1-5. ! 16. Фармацевтическая композиция, содержащая конъюгат по п.8. ! 17. Композиция по п.15, при
Claims (37)
1. Изолированная укороченная уриказа млекопитающего, содержащая аминокислотную последовательность уриказы млекопитающего, укороченную с аминоконца или карбоксиконца или и с амино- и с карбоксиконца приблизительно на 1-13 аминокислот и дополнительно содержащая аминокислотную замену приблизительно в положении 46.
2. Уриказа по п.1, дополнительно содержащая аминоконцевую аминокислоту, где данной аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин.
3. Уриказа по п.2, где аминоконцевой аминокислотой является треонин.
4. Уриказа по п.1, где заменой является замена на треонин или аланин.
5. Уриказа по п.3, где заменой является замена на треонин.
6. Уриказа по п.5, содержащая аминокислотную последовательность SEQ ID № 8.
7. Уриказа по любому из пп.1-6, где уриказа конъюгирована с полимером.
8. Конъюгат полиэтиленгликоль-уриказа, содержащий уриказу по любому из пп.1-6.
9. Конъюгат по п.8, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы.
10. Конъюгат по п.9, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы.
11. Конъюгат по п.8, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 100 кД.
12. Конъюгат по п.11, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 50 кД.
13. Конъюгат по п.12, где каждая молекула полиэтиленгликоля имела молекулярную массу от 5 кД до 20 кД.
14. Конъюгат по п.13, где каждая молекула полиэтиленгликоля имела молекулярную массу приблизительно 10 кД.
15. Фармацевтическая композиция, содержащая уриказу по любому из пп.1-5.
16. Фармацевтическая композиция, содержащая конъюгат по п.8.
17. Композиция по п.15, пригодная для повторного введения.
18. Композиция по п.16, пригодная для повторного введения.
19. Способ снижения уровней мочевой кислоты в биологической жидкости организма нуждающегося в этом пациента, включающий введение в организм пациента композиции по п.15.
20. Способ снижения уровней мочевой кислоты в биологической жидкости организма нуждающегося в этом пациента, включающий введение в организм пациента композиции по п.16.
21. Способ по п.19, где данной биологической жидкостью является кровь.
22. Способ по п.20, где данной биологической жидкостью является кровь.
23. Изолированная уриказа, содержащая аминокислотную последовательность SEQ ID № 14.
24. Изолированный укороченный белок уриказы млекопитающего по п.1, где N-концевой аминокислотой является метионин.
25. Уриказа по п.24, содержащая аминокислотную последовательность SEQ ID № 7.
26. Изолированная нуклеиновая кислота, содержащая последовательность нуклеиновой кислоты, кодирующей белок по пп.1, 3, 6, 24 или 25.
27. Изолированная нуклеиновая кислота по п.26, где последовательность нуклеиновой кислоты функционально связана с гетерологичным промотором.
28. Нуклеиновая кислота по п.27, где промотором является промотор osmB.
29. Вектор нуклеиновой кислоты, содержащий нуклеиновую кислоту по п.27.
30. Клетка-хозян, содержащая вектор по п.29.
31. Изолированная нуклеиновая кислота, содержащая последовательность нуклеиновой кислоты, кодирующую уриказу, содержащую аминокислотную последовательность SEQ ID № 7 или SEQ ID № 8.
32. Изолированная нуклеиновая кислота по п.31, где последовательность нуклеиновой кислоты содержит SEQ ID № 9 или SEQ ID № 10.
33. Изолированная нуклеиновая кислота по п.31, где последовательность нуклеиновой кислоты функционально связана с гетерологичным промотором.
34. Нуклеиновая кислота по п.33, где данным промотором является промотор osmB.
35. Вектор нуклеиновой кислоты, содержащий нуклеиновую кислоту по п.33.
36. Клетка-хозян, содержащая вектор по п.35.
37. Способ получения уриказы, включающий стадии культивирования клетки-хозяина по п.30 или 36 в таких условиях, при которых последовательность нуклеиновой кислоты экспрессируется клеткой-хозяином, и выделения экспрессированной уриказы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67057305P | 2005-04-11 | 2005-04-11 | |
US60/670,573 | 2005-04-11 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012106148/10A Division RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106116A Division RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106150/10A Division RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007141625A true RU2007141625A (ru) | 2009-05-20 |
RU2451074C2 RU2451074C2 (ru) | 2012-05-20 |
Family
ID=37075495
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007141625/10A RU2451074C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантные формы уратоксидазы и их применение |
RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106116A RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106116A RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Country Status (27)
Country | Link |
---|---|
US (12) | US8188224B2 (ru) |
EP (3) | EP3321359B1 (ru) |
JP (6) | JP2008535500A (ru) |
KR (1) | KR20080009111A (ru) |
CN (1) | CN101198693B (ru) |
AU (1) | AU2006235495B2 (ru) |
BR (1) | BRPI0612941A2 (ru) |
CA (1) | CA2604399A1 (ru) |
CY (1) | CY1124138T1 (ru) |
CZ (1) | CZ2007695A3 (ru) |
DK (1) | DK3321359T3 (ru) |
ES (2) | ES2538357T3 (ru) |
FR (1) | FR15C0067I2 (ru) |
HK (1) | HK1112021A1 (ru) |
HU (2) | HU229068B1 (ru) |
IL (1) | IL186510A (ru) |
LT (1) | LT3321359T (ru) |
MX (1) | MX2007012547A (ru) |
NZ (1) | NZ562292A (ru) |
PL (2) | PL3321359T3 (ru) |
PT (1) | PT3321359T (ru) |
RU (4) | RU2451074C2 (ru) |
SG (1) | SG161247A1 (ru) |
SI (1) | SI3321359T1 (ru) |
TW (1) | TWI366467B (ru) |
WO (1) | WO2006110819A2 (ru) |
ZA (1) | ZA200708650B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
PL3321359T3 (pl) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
RU2435847C2 (ru) | 2005-04-11 | 2011-12-10 | Савиент Фармасьютикалз, Инк. | Вариантная форма урат-оксидазы и ее использование |
US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
ES2532804T3 (es) * | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
CN102051348B (zh) * | 2009-10-27 | 2012-10-03 | 重庆富进生物医药有限公司 | 人源化重组尿酸酶及其突变体 |
US8940861B2 (en) | 2010-04-08 | 2015-01-27 | Georgia Tech Research Corporation | Variants of ancestral uricases and uses thereof |
CN102634492B (zh) | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
CN102260653B (zh) * | 2011-06-30 | 2013-04-03 | 荣俊 | 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法 |
CN103834623B (zh) * | 2014-02-11 | 2017-11-07 | 中国药科大学 | 具有催化活性的人源尿酸氧化酶 |
US11098289B2 (en) | 2015-05-15 | 2021-08-24 | Medimmune, Llc | Uricase sequences and methods of treatment |
JP2019535819A (ja) * | 2016-11-11 | 2019-12-12 | ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーHorizon Pharma Rheumatology Llc | プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用 |
CN111909906B (zh) * | 2019-05-10 | 2024-04-19 | 重庆派金生物科技有限公司 | 聚乙二醇修饰的尿酸氧化酶 |
WO2021042055A1 (en) * | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
CN112980808A (zh) * | 2019-12-12 | 2021-06-18 | 深圳迈瑞生物医疗电子股份有限公司 | 尿酸酶、及其制备方法和用途 |
CN113144174B (zh) * | 2020-01-22 | 2023-07-04 | 杭州远大生物制药有限公司 | 治疗高尿酸相关性疾病的药物 |
KR20230110281A (ko) | 2020-11-03 | 2023-07-21 | 프로탈릭스 리미티드 | 변형된 유리카제(uricase) 및 이의 용도 |
CN114438048A (zh) * | 2020-11-05 | 2022-05-06 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
CN114438047A (zh) * | 2020-11-05 | 2022-05-06 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
CN115197923A (zh) * | 2021-04-09 | 2022-10-18 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
CN117230034A (zh) * | 2023-10-16 | 2023-12-15 | 临沂大学 | 一种高稳定性哺乳动物尿酸氧化酶突变体 |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE279489C (ru) | ||||
DE279486C (ru) | ||||
US1141973A (en) | 1911-05-22 | 1915-06-08 | Jesse W Nichols | Can-cap with vent-shield. |
DE837379C (de) | 1950-04-20 | 1955-08-16 | Nordwind G M B H | Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe |
US3451996A (en) | 1968-02-12 | 1969-06-24 | Thompson Farms Co | Method for the preparation of heparin |
US3616231A (en) | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
US3613231A (en) | 1969-07-25 | 1971-10-19 | Paul F Pugh | Method for manufacturing high voltage cable systems |
US3931399A (en) | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4027676A (en) | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
US4169764A (en) | 1975-08-13 | 1979-10-02 | Ajinomoto Co., Inc. | Process for production of urokinase |
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US4064010A (en) | 1976-07-21 | 1977-12-20 | Eastman Kodak Company | Purification of uricase |
US4301153A (en) | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
US4425431A (en) | 1978-04-20 | 1984-01-10 | Toyo Soda Manufacturing Co., Ltd. | Production of an allose-containing polysaccharide |
US4312979A (en) | 1978-04-20 | 1982-01-26 | Toyo Soda Manufacturing Co., Ltd. | Polysaccharides containing allose |
JPS6031472B2 (ja) | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
US4251431A (en) | 1979-01-16 | 1981-02-17 | Shell Oil Company | Lubricating greases |
JPS5599189A (en) | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
JPS55135590A (en) | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
DE2943016C2 (de) | 1979-10-24 | 1984-09-06 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Verfahren zur Reinigung von Interferon |
JPS5651995A (en) | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
DE3005897A1 (de) | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
FR2475900A1 (fr) | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
CH651308A5 (de) | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
JPS5740503A (en) | 1980-08-22 | 1982-03-06 | Seikagaku Kogyo Co Ltd | Separation of saccharides |
US4315852A (en) | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
FR2497006A1 (fr) | 1980-12-24 | 1982-06-25 | Ind Electro Ste Gle | Contacts electriques pour cables coaxiaux et cables bifilaires |
JPS57192435A (en) | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
DE3126759A1 (de) | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung |
US4450103A (en) | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
US4485176A (en) | 1982-06-28 | 1984-11-27 | E. I. Du Pont De Nemours & Company | Turbidimetric method for measuring protein in urine and cerebrospinal fluid |
EP0109688A3 (en) | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Improved complexes, processes for obtaining them and formulations containing such complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
USD279486S (en) | 1983-04-25 | 1985-07-02 | International Jensen Incorporated | Controller for a video game or the like |
US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
JPH0671425B2 (ja) | 1985-06-05 | 1994-09-14 | サッポロビール株式会社 | ウリカ−ゼおよびその製造法 |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
AU597924B2 (en) | 1985-12-11 | 1990-06-14 | Natinco Nv | Solubilization of protein aggregates |
DD279486A1 (de) | 1986-03-10 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JPS6255079A (ja) | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DD279489A1 (de) | 1986-12-11 | 1990-06-06 | Leuna Werke Veb | Verfahren zur herstellung optisch transparenter epoxidharzformmassen |
JPS63203548A (ja) | 1987-02-12 | 1988-08-23 | 四国化工機株式会社 | 飲料用密封容器の製造装置 |
AU612133B2 (en) | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
CA1305285C (en) | 1987-04-21 | 1992-07-14 | Malcolm Roy Brandon | Production of proteins in active forms |
AU609824B2 (en) | 1987-06-15 | 1991-05-09 | Southern Cross Biotech Pty Ltd. | Production of proteins in active forms |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
CA1286591C (en) | 1987-12-18 | 1991-07-23 | Douglas B. Taylor | Apparatus for opening and closing roll-up door |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
JPH01216939A (ja) | 1988-02-24 | 1989-08-30 | Hoechst Japan Kk | 末熟児頭蓋内出血阻止剤 |
US4945086A (en) | 1988-05-03 | 1990-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Smooth muscle cell growth inhibitor |
US5955336A (en) | 1988-08-17 | 1999-09-21 | Toyo Boseki Kabushiki Kaisha | DNA sequence for uricase and manufacturing process of uricase |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
JP3148208B2 (ja) | 1988-10-31 | 2001-03-19 | 富士ゼロックス株式会社 | マルチ出力トレイ付プリントサーバおよびプリントシステム |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
NZ234453A (en) | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
KR0159107B1 (ko) | 1989-07-13 | 1998-11-16 | 쟝 르쌍드뢰 | 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포 |
JPH0354581A (ja) | 1989-07-24 | 1991-03-08 | Nec Corp | 電子写真系プリンタの現像カートリッジ |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
KR927003090A (ko) | 1989-08-23 | 1992-12-17 | 하다사 메디칼 오르가니제이션 | 헤파린효소를 포함하는 상처 치유 약제 |
JPH03148298A (ja) | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | 修飾ペプチドおよびその製造方法 |
JPH03148208A (ja) | 1989-11-02 | 1991-06-25 | Mikimoto Seiyaku Kk | 皮膚外用剤 |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
ES2141108T3 (es) | 1991-07-02 | 2000-03-16 | Inhale Inc | Metodo y dispositivo para proporcionar medicamentos en aerosol. |
YU66892A (sh) | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
JP3148298B2 (ja) | 1991-09-02 | 2001-03-19 | 帝人株式会社 | 軽量複合成形物の製造法 |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
AU6240494A (en) | 1993-02-16 | 1994-09-14 | Enzon, Inc. | Ribosome inactivating protein compositions having reduced antigenicity |
US6385312B1 (en) | 1993-02-22 | 2002-05-07 | Murex Securities, Ltd. | Automatic routing and information system for telephonic services |
JP3875730B2 (ja) | 1993-02-22 | 2007-01-31 | サノフィ・アベンティス株式会社 | 自己免疫疾患の予防治療剤 |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
JPH06255079A (ja) | 1993-03-08 | 1994-09-13 | Akira Totsuka | 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法 |
KR960701649A (ko) | 1993-04-09 | 1996-03-28 | 심파쓰 | Xa인자 억제활성을 가진 신규 폴리펩티드 |
US5783421A (en) | 1993-04-09 | 1998-07-21 | Bio-Technology General Corp. | DNA encoding novel polypeptide having Factor Xa inhibitory activity |
WO1994023740A1 (en) | 1993-04-22 | 1994-10-27 | Celtrix Pharmaceuticals, Inc. | Conjugates of growth factor and bone resorption inhibitor |
WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
AU685187B2 (en) | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
DK0730470T3 (da) | 1993-11-10 | 2002-06-03 | Enzon Inc | Forbedrede interferonpolymerkonjugater |
US5795776A (en) | 1994-03-22 | 1998-08-18 | Bio-Technology General Corp. | Expression plasmids regulated by an OSMB promoter |
FI96317C (fi) | 1994-05-31 | 1996-06-10 | Exavena Oy | Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi |
DE4423131A1 (de) | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5856451A (en) | 1994-12-07 | 1999-01-05 | Novo Nordisk A/S | Method for reducing respiratory allergenicity |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
IL116696A (en) | 1995-01-25 | 1999-08-17 | Bio Technology General Corp | Production of enzymatically active recombinant carboxypeptidase b |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
FR2733914B1 (fr) | 1995-05-11 | 1997-08-01 | Sanofi Sa | Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation |
JPH09154581A (ja) | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
ES2275300T3 (es) | 1997-01-15 | 2007-06-01 | Phoenix Pharmacologics, Inc. | Factor de necrosis tumoral modificado. |
US5816397A (en) | 1997-01-21 | 1998-10-06 | Ogio International, Inc. | Golf club carrying apparatus |
EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
KR100369838B1 (ko) | 1997-02-26 | 2003-09-29 | 주식회사 엘지생명과학 | 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법 |
US6821763B2 (en) | 1997-07-04 | 2004-11-23 | Ajinomoto Co., Inc. | Process for producing microbial transglutaminase |
JPH1175876A (ja) * | 1997-07-04 | 1999-03-23 | Ajinomoto Co Inc | 新規な微生物トランスグルタミナーゼの製造法 |
JP2002517406A (ja) | 1998-06-01 | 2002-06-18 | ジェネンテック・インコーポレーテッド | イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離 |
PT1100880E (pt) * | 1998-08-06 | 2011-01-13 | Univ Duke | Urato-oxidase |
JP5183836B2 (ja) | 1998-08-06 | 2013-04-17 | マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド | Peg−尿酸酸化酵素結合体およびその使用 |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
US20060188971A1 (en) | 1998-08-06 | 2006-08-24 | Duke University | Urate oxidase |
EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
KR19980069019U (ko) | 1998-09-29 | 1998-12-05 | 양영석 | 신축성 핸드폰 케이스 |
US6425448B1 (en) | 2001-01-30 | 2002-07-30 | Cdx Gas, L.L.P. | Method and system for accessing subterranean zones from a limited surface area |
US6429860B1 (en) | 1999-06-15 | 2002-08-06 | Visicomp, Inc. | Method and system for run-time visualization of the function and operation of a computer program |
RU2286711C2 (ru) | 2000-02-14 | 2006-11-10 | Фёрст Опинион Корпорэйшн | Система и способ автоматической диагностики |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US20050084478A1 (en) | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
NZ528076A (en) | 2001-03-02 | 2005-09-30 | Medimmune Inc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules |
US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US20040105839A1 (en) | 2001-11-28 | 2004-06-03 | Myung-Ok Park | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
ZA200504990B (en) | 2003-01-09 | 2006-08-30 | Genentech Inc | Purification of polypeptides |
JP4273998B2 (ja) | 2004-02-26 | 2009-06-03 | 学校法人東海大学 | プロテオーム解析用試料の調製方法 |
WO2005110386A2 (en) | 2004-04-13 | 2005-11-24 | Wisconsin Alumni Research Foundation | Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers |
CN103088038B (zh) | 2004-07-12 | 2015-06-24 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
GB0420888D0 (en) | 2004-09-20 | 2004-10-20 | Photopharmica Ltd | Compounds and uses |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
PL3321359T3 (pl) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
US20080159976A1 (en) | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
RU2435847C2 (ru) | 2005-04-11 | 2011-12-10 | Савиент Фармасьютикалз, Инк. | Вариантная форма урат-оксидазы и ее использование |
CA2642656A1 (en) | 2006-02-22 | 2007-09-07 | Novartis Pharma Ag | System for delivering nebulized cyclosporine and methods of treatment |
ES2532804T3 (es) | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
NL1031926C2 (nl) | 2006-05-31 | 2007-12-03 | X Flow Bv | Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum. |
US20080145876A1 (en) | 2006-11-21 | 2008-06-19 | University Of Southern California | Poly(ethylene glycol) anti-body detection assays and kits for performing thereof |
JP5813919B2 (ja) | 2007-10-10 | 2015-11-17 | 協和発酵バイオ株式会社 | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 |
CN101168052A (zh) | 2007-10-26 | 2008-04-30 | 西安交通大学 | 一种防治高尿酸血症及痛风的肠溶制剂 |
ES2521674T3 (es) | 2008-09-15 | 2014-11-13 | Transition Therapeutics Ireland Limited | Métodos de tratamiento de hiperuricemia y estados patológicos asociados |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
JP5451464B2 (ja) | 2010-03-09 | 2014-03-26 | キヤノン株式会社 | 帯電装置 |
EP2560642A4 (en) | 2010-03-30 | 2013-12-18 | Ardea Biosciences Inc | TREATMENT OF GICHT |
CN104066324A (zh) | 2011-11-04 | 2014-09-24 | 西玛贝医药公司 | 治疗痛风急性发作的方法 |
JP5746101B2 (ja) | 2012-06-18 | 2015-07-08 | コスメディ製薬株式会社 | マイクロニードルの迅速溶解法 |
GB2512876A (en) | 2013-04-09 | 2014-10-15 | Image Analysis Ltd | Methods and apparatus for quantifying inflammation |
LT3536685T (lt) | 2014-04-04 | 2022-04-25 | Pfizer Inc. | Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių |
MX2018011012A (es) | 2016-03-11 | 2019-03-28 | Selecta Biosciences Inc | Formulaciones y dosis de uricasa pegilada. |
WO2018007878A1 (en) | 2016-07-05 | 2018-01-11 | CanTrust LifeScience Corp. | Methods of treating and preventing gout and lead nephropathy |
US20220409620A1 (en) | 2016-11-11 | 2022-12-29 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
JP2019535819A (ja) | 2016-11-11 | 2019-12-12 | ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーHorizon Pharma Rheumatology Llc | プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用 |
BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
US20200237879A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
WO2020160324A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
WO2021042055A1 (en) | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
KR20230086660A (ko) | 2020-08-10 | 2023-06-15 | 호라이즌 테라퓨틱스 유에스에이, 인크. | 통풍의 치료 방법 |
-
2006
- 2006-04-11 PL PL17192971T patent/PL3321359T3/pl unknown
- 2006-04-11 CA CA 2604399 patent/CA2604399A1/en not_active Abandoned
- 2006-04-11 JP JP2008505664A patent/JP2008535500A/ja active Pending
- 2006-04-11 MX MX2007012547A patent/MX2007012547A/es active IP Right Grant
- 2006-04-11 LT LTEP17192971.4T patent/LT3321359T/lt unknown
- 2006-04-11 ES ES06749889.9T patent/ES2538357T3/es active Active
- 2006-04-11 EP EP17192971.4A patent/EP3321359B1/en active Active
- 2006-04-11 AU AU2006235495A patent/AU2006235495B2/en active Active
- 2006-04-11 EP EP15156612.2A patent/EP2947145A1/en not_active Withdrawn
- 2006-04-11 SI SI200632400T patent/SI3321359T1/sl unknown
- 2006-04-11 US US11/918,297 patent/US8188224B2/en active Active
- 2006-04-11 TW TW095112937A patent/TWI366467B/zh active
- 2006-04-11 NZ NZ562292A patent/NZ562292A/en not_active IP Right Cessation
- 2006-04-11 BR BRPI0612941-2A patent/BRPI0612941A2/pt not_active Application Discontinuation
- 2006-04-11 ES ES17192971T patent/ES2856881T3/es active Active
- 2006-04-11 EP EP20060749889 patent/EP1871874B1/en active Active
- 2006-04-11 CZ CZ20070695A patent/CZ2007695A3/cs unknown
- 2006-04-11 CN CN2006800210183A patent/CN101198693B/zh active Active
- 2006-04-11 PT PT171929714T patent/PT3321359T/pt unknown
- 2006-04-11 WO PCT/US2006/013660 patent/WO2006110819A2/en active Search and Examination
- 2006-04-11 PL PL387691A patent/PL215285B1/pl unknown
- 2006-04-11 HU HU0700730A patent/HU229068B1/hu active Protection Beyond IP Right Term
- 2006-04-11 KR KR20077026113A patent/KR20080009111A/ko active Search and Examination
- 2006-04-11 RU RU2007141625/10A patent/RU2451074C2/ru not_active IP Right Cessation
- 2006-04-11 DK DK17192971.4T patent/DK3321359T3/da active
- 2006-04-11 SG SG201002407-3A patent/SG161247A1/en unknown
- 2006-04-11 HU HUE17192971A patent/HUE052976T2/hu unknown
-
2007
- 2007-10-09 IL IL186510A patent/IL186510A/en active IP Right Grant
- 2007-10-10 ZA ZA200708650A patent/ZA200708650B/xx unknown
-
2008
- 2008-06-19 HK HK08106827.8A patent/HK1112021A1/xx unknown
-
2012
- 2012-02-20 RU RU2012106150/10A patent/RU2012106150A/ru not_active Application Discontinuation
- 2012-02-20 RU RU2012106116A patent/RU2610680C9/ru not_active IP Right Cessation
- 2012-02-20 RU RU2012106148/10A patent/RU2012106148A/ru not_active Application Discontinuation
- 2012-05-01 US US13/461,170 patent/US8541205B2/en active Active
-
2013
- 2013-01-23 JP JP2013009968A patent/JP2013135676A/ja not_active Withdrawn
- 2013-08-21 US US13/972,167 patent/US9017980B2/en active Active
-
2015
- 2015-01-07 JP JP2015001805A patent/JP2015107122A/ja active Pending
- 2015-03-27 US US14/671,246 patent/US9670467B2/en active Active
- 2015-10-07 FR FR15C0067C patent/FR15C0067I2/fr active Active
-
2016
- 2016-07-04 JP JP2016132216A patent/JP2016171819A/ja not_active Withdrawn
-
2017
- 2017-04-18 US US15/490,736 patent/US20170298326A1/en not_active Abandoned
- 2017-07-13 US US15/649,478 patent/US10160958B2/en active Active
- 2017-07-13 US US15/649,398 patent/US20170313993A1/en not_active Abandoned
- 2017-07-13 US US15/649,488 patent/US9926538B2/en active Active
- 2017-07-13 US US15/649,462 patent/US9926537B2/en active Active
- 2017-10-18 JP JP2017201898A patent/JP2018015005A/ja active Pending
-
2018
- 2018-11-28 US US16/202,743 patent/US10731139B2/en active Active
-
2019
- 2019-01-04 JP JP2019000199A patent/JP2019070006A/ja active Pending
-
2020
- 2020-06-24 US US16/911,074 patent/US11345899B2/en active Active
-
2021
- 2021-03-02 CY CY20211100173T patent/CY1124138T1/el unknown
-
2022
- 2022-04-19 US US17/724,091 patent/US11781119B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007141625A (ru) | Вариантные формы уратоксидазы и их применение | |
Hwang et al. | Cell adhesion biomaterial based on mussel adhesive protein fused with RGD peptide | |
US6121236A (en) | Multivalent ligands which modulate angiogenesis | |
CN105916877A (zh) | 长效胰岛素及其用途 | |
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
KR101145990B1 (ko) | 시아노비린 변이체-중합체 콘쥬게이트 | |
KR102494646B1 (ko) | 안정화된 피브로넥틴 기반 스캐폴드 분자 | |
IL222515A (en) | A mutant human albumin containing unnatural amino acids | |
Yamazaki et al. | Collagen‐like cell‐penetrating peptides | |
CN113186109A (zh) | 一种酿酒酵母表达长效重组纤连蛋白及其在化妆品中的应用 | |
WO2005026375A3 (en) | Recombinant carrier molecule for expression, delivery and purification of target polypeptides | |
DE602005025141D1 (de) | In Zellen eindringende Peptide als Träger für Moleküle | |
JP2008518622A5 (ru) | ||
CN116925240A (zh) | 一种重组胶原蛋白及其表达方法和应用 | |
CN112500495A (zh) | 一种elp-ⅲ型胶原蛋白的纯化方法及应用 | |
JP6982395B2 (ja) | インターロイキン10の産生量増加剤 | |
JPWO2016136708A1 (ja) | 膜透過性ペプチドを側鎖に有する高分子化合物 | |
US20130237476A1 (en) | Adipose tissue targeted peptides | |
CN105294851B (zh) | 与几丁质特异结合的碱性成纤维细胞生长因子及其编码基因、制备方法与应用 | |
WO2007068053A1 (en) | Recombinant protein production | |
CN103980366B (zh) | 一种白介素融合蛋白及其制备方法和应用 | |
JP2011030453A (ja) | 細胞の生産方法 | |
US20210079042A1 (en) | Peptide hydrogels and use thereof | |
RU2582569C2 (ru) | Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом | |
US11648279B2 (en) | Composition for cell transplant, and method for cell transplant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20141209 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190412 |